Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry
Open Access
- 5 January 2024
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 17
Abstract
Background: Infliximab seems to be the most efficacious of the three available anti-TNF agents for ulcerative colitis (UC) but little is known when it is used as the second anti-TNF. Objectives: To compare the clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in UC patients. Design: Retrospective observational study. Methods: Patients from the ENEIDA registry treated consecutively with infliximab and a subcutaneous anti-TNF (or vice versa), naïve to other biological agents, were identified and grouped according to the administration route of the first anti-TNF into IVi (intravenous initially) or SCi (subcutaneous initially). Results: Overall, 473 UC patients were included (330 IVi and 143 SCi). Clinical response at week 14 was 42.7% and 48.3% in the IVi and SCi groups (non-statistically significant), respectively. Clinical remission rates at week 52 were 32.8% and 31.4% in the IVi and SCi groups (nonsignificant differences), respectively. A propensity-matched score analysis showed a higher clinical response rate at week 14 in the SCi group and higher treatment persistence in the IVi group. Regarding long-term outcomes, dose escalation and discontinuation due to the primary failure of the first anti-TNF and more severe disease activity at the beginning of the second anti-TNF were inversely associated with clinical remission. Conclusion: The use of a second anti-TNF for UC seems to be reasonable in terms of efficacy, although it is particularly reduced in the case of the primary failure of the first anti-TNF. Whether the second anti-TNF is infliximab or subcutaneous does not seem to affect efficacy.Keywords
Funding Information
- AbbVie
- Pfizer
- Galápagos
- Janssen Pharmaceutica
- Biogen
- Takeda Pharmaceutical Company
This publication has 25 references indexed in Scilit:
- Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designsExpert Review of Gastroenterology & Hepatology, 2015
- Systematic review with meta‐analysis: the efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose previous anti‐TNF treatment has failedAlimentary Pharmacology & Therapeutics, 2015
- Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitisAlimentary Pharmacology & Therapeutics, 2014
- An Overview of the Natural History of Inflammatory Bowel DiseasesDigestive Diseases, 2014
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2014
- Adalimumab in active ulcerative colitis: A “real-life” observational studyDigestive and Liver Disease, 2013
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2013
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2012
- Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximabAlimentary Pharmacology & Therapeutics, 2010
- Systematic review: infliximab therapy in ulcerative colitisAlimentary Pharmacology & Therapeutics, 2006